You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

848 Results
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    aXitinib - In combination with pembrolizumab for first-line advanced or metastatic renal cell carcinoma
New Drug Funding Program
    Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
aXitinib,
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Azacitidine in combination with Venetoclax (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Exceptional Access Program
    venetoclax - Venetoclax in combination with azacitidine - Previously untreated acute myeloid leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
azaCITIDine,
venetoclax
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2022
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
DOCEtaxel,
darolutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
carfilzomib (Unfunded),
dexamethasone,
selinexor (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
tislelizumab (Unfunded),
gemcitabine,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2024
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
pembrolizumab (Unfunded),
pemetrexed,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
New
May 2025
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trastuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
PACLitaxel,
CARBOplatin,
bevacizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2023
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2023
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of metastatic gastric cancer (mGC) or adenocarcinoma of the gastroesophageal junction (GEJ) in adult patients, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trifluridine / tipiracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2022

Pages